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Objective. B cell abnormalities characterized by autoantibody production and polyclonal B cell 
activation play an important role in the pathogenesis of systemic sclerosis (SSc). IL-10 
producing regulatory B (Breg) cells play an important role in the negative immune response. 
Recently, we identified a human Breg cell subset and it was predominantly found within the 
CD24hiCD27+ B cell subpopulation. However, the role of Breg cells in SSc remains unknown. In 
this study, we investigated the clinical association of Breg cells in SSc patients.  
Methods. Blood IL-10 producing Breg cell levels were determined by FACS in 35 SSc patients 
and 30 healthy subjects. In a follow-up study, we analyzed 6 individual dcSSc patients before 
and after treatment. 
Results. The frequency of blood Breg cells was significantly lower in SSc patients than in 
healthy controls (P<0.0001). Similarly, the frequency of CD24hiCD27+ B cells was significantly 
lower in SSc patients with than in healthy controls (P<0.0001). SSc patients with decreased Breg 
cell levels more frequently had interstitial lung disease (P<0.05). Furthermore, Breg cell levels 
correlated negatively with the titer of anti-topoisomerase I Ab and anticentromere Ab in SSc 
patients. For a follow-up study, Breg cell levels in dcSSc patients after treatment were found to 
be significantly increased comparing with that before treatment (P<0.05), accompanied with 
decreased disease activity. Thus, Breg cell levels inversely correlated with disease activity of 
SSc. 
Conclusion. These results suggest that decreased Breg cell levels may contribute to the 
development of SSc.  
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Key messages 
Regulatory B cells are decreased in patients with systemic sclerosis. 
Decreased levels of regulatory B cells may acceralete autoantibody production in patients with 
systemic sclerosis . 
Regulatory B cell levels inversely correlated with disease activity of SSc.
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Systemic sclerosis (SSc) is a connective tissue disorder characterized by fibrosis in the skin and 
various internal organs, with autoimmune background. The two subsets were termed diffuse 
cutaneous (dcSSc) and limited cutaneous SSc (lcSSc) [1]. Autoantibodies are positive in over 
90% of patients and these autoantibodies (Abs) react to various intracellular components. The 
autoantibodies associated with SSc include anti-DNA topoisomerase I and anticentromere Abs. It 
has been reported that SSc patients have distinct abnormalities of blood B lymphocyte 
compartments characterized by expanded naive B cells and activated memory B cells [2]. 
Furthermore, B cell depletion therapy suppresses the development of skin fibrosis in the tight-skin 
mouse [3, 4]. In addition, several recent studies have revealed a possible beneficial effect of 
antihuman CD20 antibody (rituximab) therapy for SSc patients [5].  
Regulatory B (Breg) cells that produce IL-10 is now recognized as an important 
component of the immune system. Remarkably, Breg cells are potent negative regulators of 
inflammation and autoimmunity in mouse models of disease in vivo. Our recent study revealed 
that Breg cells play an inhibitory role in murine sclerodermatous chronic graft-versus-host 
disease (Scl-cGVHD), a mouse model of scleroderma [6]. Breg cells in humans normally 
represent <1% of peripheral blood B cells [7]. The phenotype of human Breg cells is reported to 
be CD24hiCD27+ B cell subset [7] or CD19+CD24hiCD38hi B cells [8]. It has been reported that 
pan-B cell depletion, including regulatory B cell depletion, worsens autoimmunity in humans [9]. 
Pan-B cell depletion is not always a beneficial effect in autoimmunity. Therefore, it is necessary 
to investigate Breg cells in systemic sclerosis. 
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Patients and Methods 
 Patients. Serum samples were obtained from 35 Japanese SSc patients (29 females and 
6 males). All patients fulfilled the criteria for SSc proposed by the American College of 
Rheumatology [10]. Their median (range) age was 57 (18-71) years and the median (range) 
disease duration was 2.0 (0.1-24) years. These patients were grouped according to the 
classification system proposed by LeRoy et al. [1]: 16 patients had dcSSc and 19 patients had 
lcSSc. Anti-topoisomerase I Abs were positive for 14 patients; anticentromere Abs for 11; and 
anti-RNA polymerases I/III Abs for 3. The disease duration was calculated from the time of the 
first clinical event (other than Raynaud’s phenomenon) that was a clear manifestation of SSc. 
Five patients were treated with a low-dose prednisolone (1-10 mg/day). Eight patients were 
treated with an intermediate-dose prednisolone (11-20 mg/day). In addition to an 
intermediate-dose of steroid treatment, 2 patients were treated with cyclosporine (2-3 mg/kg/day) 
and 2 patients were treated with intravenous cyclophosphamide pulse (500 mg/m2). In a 
follow-up study, we analyzed 6 individual patients with dcSSc before and after 
immunosuppressant agents. At the first blood sampling, 1 patient was treated with 12 mg/day of 
prednisolone, while remaining 5 SSc patients did not received any immunosuppressant agents. 
Afterward, 4 patients were treated with 20-40 mg/day of prednisolone. Furthermore, 2 patients 
were treated with 6-cycle of intravenous cyclophosphamide pulse (500mg/m2) in addition to 20 
mg/day of prednisolone. Second blood sampling were taken after treatment. As disease control in 
this study, we also examined serum samples from 10 patients with dermatomyositis (DM) that 
fulfilled the American College of Rheumatology criteria [11] and Bohan and Peter criteria [12], 
respectively. Age- and sex-matched 30 healthy Japanese individuals were used as healthy 
controls. The whole study was approved by the ethics committee of the Institute of Medical, 
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Pharmaceutical and Health Sciences, Kanazawa University, and informed consent was obtained 
from all patients.  
Clinical assessment. Complete medical histories, physical examinations, and laboratory 
tests were conducted for all patients at the time of blood sampling, with limited evaluations 
during follow-up visits. Skin score was measured by scoring technique of the modified Rodnan 
total skin thickness score (modified Rodnan TSS) . Organ system involvement was defined as 
described previously [13]. 
Antibodies and flow cytometric analysis.  
Anti-human mAbs included: CD19, CD24, CD27 from BD Biosciences (San Diego, CA, 
USA) and anti-IL-10 mAb from BioLegend (San Diego, CA, USA). Blood samples (50 µl) were 
stained at 4°C using mAbs for 20 minutes. Cells were analyzed on a BD FACSCantTM II flow 
cytometer (BD Biosciences).  
Analysis of IL-10 production. Heparinized blood samples were collected. Peripheral 
blood mononuclear cells (PBMCs) were resuspended (2 x 106 cells/ml) in medium and 
stimulated with CpG (ODN 2006, 10 µg/ml; Invivogen), CD40L (1 µg/ml; R&D Systems, 
Minneapolis, MN, USA), PMA (50 ng/ml; Sigma), ionomycin (1 µg/ml; Sigma), Brefeldin A 
(1X solution/ml; BioLegend). Stained cells were fixed and permeabilized using a 
Cytofix/Cytoperm kit (BD Biosciences) and stained with anti-IL-10 mAb. 
Statistical Analysis. Statistical analyses were performed using Student’s t-test for 
comparison of sample means between two groups or one-way analysis of variance with 
Bonferroni post hoc tes for comparisons of more than two groups. The Pearson product–moment 
correlation coefficient was used to examine the relationship between two continuous variables. 
Wilcoxon matched paired rank test was used for matched paired samples. P-values <0.05 were 
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Breg cell levels in SSc. The frequency of IL-10 producing Breg cells was significantly 
lower in SSc patients [5.43 (2.38-13.10) %] than in healthy controls [11.60 (4.29-18.80) %, 
P<0.0001; Fig. 1A-B]. The absolute number of Breg cells was also significantly lower in SSc 
patients [1.68 (0.08-15.30) x 106/L] than in healthy controls [4.31 (1.03-24.52) x 106/L, 
P<0.0001]. By contrast, the frequency of Breg cells in DM patients [9.57 (6.90-14.50) %] was 
comparable to that in healthy controls (Fig. 1B). Similarly, the frequency of CD24hiCD27+ B 
cells was significantly lower in SSc patients [16.2 (7.6-42.6) %] than in healthy controls [28.3 
(17.1-62.7), P<0.0001]. The absolute number of CD24hiCD27+ B cells was also significantly 
lower in SSc patients [3.43 (0.22-65.98) x 106/L] than in healthy controls [12.99 (3.94-64.25) x 
106/L, P<0.01].  
Clinical correlation of Breg cell levels in SSc. Breg cell levels were decreased in 26% 
(9/35) of SSc patients in 26% (5/19) of dcSSc patients and in 25% (4/12) of lcSSc patients. There 
was no significant difference in disease duration between patients with decreased Breg cell levels 
and those with normal levels (Supplementary Table 1). In addition, there was no significant 
difference in modified Rodnan TSS and clinical features. SSc patients with decreased Breg cell 
levels more frequently had interstitial lung disease (P<0.05). In contrast, there was no significant 
difference in the prevalence of esophagus, heart, kidney, joint and muscle involvement. The 
frequency of elevated CRP levels was significantly increased in SSc patients with decreased 
Breg cell levels compared with normal levels (P<0.05). Furthermore, Breg cell levels correlated 
negatively with CRP in SSc patients (P<0.05, r=-0.343; Supplementary Fig. 1), although Breg 
cell levels did not correlated with CRP in healthy control and other diseases accompanied by 
elevated CRP levels, such as cellulitis and erysipelas (data not shown). Collectively, Breg cell 
levels may not correlate with disease severity. 
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Autoimmunity plays an important role in the pathogenesis of scleroderma. It was reported that 
the titer of a scleroderma specific autoantibody, such as anti-topoisomerase I Ab, reflects the 
severity of skin sclerosis in SSc patients [14]. Decreased levels of Breg cells might accelerate the 
autoimmunity of scleroderma. As a result, Breg cell levels were found to correlate negatively 
with the titer of anti-topoisomerase I and anticentromere Abs in SSc patients (P<0.05, r=-0.533; 
P<0.05, r=-0.684, respectively, Supplementary Fig. 1). Thus, decreased Breg cell levels were 
generally associated with the autoimmunity of SSc, rather than the severity of SSc. 
Breg cell as a marker of disease activity. 
To determine whether Breg cell levels are inversely correlated with disease activity of SSc, we 
analyzed 6 indivisual patient with dcSSc before and after treatment. Disease activity was defined 
as modified Rodnan TSS. After treatment, disease activity in 6 patients with dcSSc was declined, 
since modified Rodnan TSS in dsSSc patients were significantly decreased after treatment 
(P<0.01, Fig. 2). Breg and CD24hiCD27+ B cell levels in dcSSc patients after treatment were 
found to be significantly increased comparing with that before treatment (P<0.01 and P<0.05, 
respectively, Fig. 2), accompanied with decreased disease activity. To confirm whether 
immunosuppressant agents increase Breg cell levels, we compared Breg cell levels between the 
patients treated with immunosuppressant or not. Breg cell levels in SSc patients treated with 
immunosuppressant was tend to increased compared with that in SSc patients without treatment, 
while there was no significant difference (Supplementary Fig. 2). Taken together, Breg cell 
levels inversely correlated with disease activity of SSc. 
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Discussion 
This is the first report to reveal decreased Breg cell levels in SSc. Decreased Breg cell 
levels were associated with the prevalence of interstitial lung disease. In addition, Breg cell 
levels correlated negatively with the titer of anti-topoisomerase I and anticentromere Ab in SSc 
patients. Although Breg cell levels did not correlate with the severity of skin sclerosis, Breg cell 
levels inversely correlated with disease activity of SSc. Therefore, decreased Breg cell levels 
were generally associated with pathogenesis of SSc. 
It has been suggested that Th1 cytokines, such as interferon-γ and IL-2, generally decrease 
extracellular matrix deposition, whereas Th2 cytokines, such as IL-4, IL-5, IL-6, and IL-13, 
increase it [15]. To date, B cells have primarily been studied in the roles of effector B cells, 
which positively regulate the immune response via antibody production and IL-6 secretion. 
However, Breg cells have been identified and it was consequently revealed that B cells 
negatively control the immune response via IL-10 secretion [16]. Thus, B cells have two 
conflicting subsets. We elucidated the role of these two conflicting subsets in a mouse model of 
experimental autoimmune encephalomyelitis (EAE) [17]. EAE was exacerbated when B cells 
were depleted in the early phase, whereas it improved when B cells were depleted in the late 
phase. These results indicate that in the early phase, Breg cells play a major role and the lack of 
Breg cells exacerbates EAE. On the other hand, in the late phase, effector B cells are dominant 
and the lack of effector B cells improves EAE. These results reveal that both effector and 
regulatory B cells are involved in autoimmune disease and that the weights of their roles differ 
according to the disease stage. These results also indicate that Breg cells are involved in the 
onset of autoimmune disease because they are important in the early phase. In the current study, 
Breg cell levels were lower in SSc patients than in healthy individuals; however, we found no 
correlation with severity. On the other hand, a decreased level of Breg cells correlated with a 
 11 
high autoantibody titer. Furthermore, Breg cell levels inversely correlated with disease activity of 
SSc. We recently reported that Breg cells are important in the suppression of Scl-cGVHD, a 
mouse model of systemic sclerosis [6]. The lack of Breg cells induced severe Scl-cGVHD, while 
replacement of Breg cells in the early phase restored the exacerbated Scl-cGVHD. However, 
replacement of Breg cells in the late phase had no effect on Scl-cGVHD. This suggests that Breg 
cells may play an important role in the onset of Scl-cGVHD. Thus, Breg cells are important for 
the pathogenesis of scleroderma. 
Two large randomized controlled trials of Rituximab, which depletes human pan-B cells, 
were conducted with SLE patients with the expectation that it would be effective; however, it 
failed to achieve the primary endpoints [18, 19]. This ineffectiveness may have been due to the 
existence of Breg cells. If Breg cells are dominant in a patient with SLE, B cell depletion will 
worsen the condition of the patient with SLE. Thus, the effect of pan-B cell depletion depends on 
the balance of Breg cells versus effector B cells in the patient. A clinical trial is currently 
examining B cell depletion in systemic sclerosis, so it will be necessary to consider the existence 
of Breg cells in the future. Selective B cell depletion, which retains Breg cells, is the ideal 
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Figure 1. IL-10 producing regulatory B cell frequencies in SSc patients. (A, left panel) 
Representative B cell cytoplasmic IL-10 expression by control (Ctrl) individuals and SSc 
patients with after in vitro 48 h CD40L+CpG stimulation, with PMA, ionomycin, Brefeldin A 
added during the final 5 h of culture. (A, right panel) Representative CD24hiCD27+ B cells in 
Ctrl individuals and SSc patients. (B) IL-10 producing regulatory B cell and CD24hiCD27+ B cell 
frequencies of Ctrl individuals, SSc and dermatomyositis (DM) patients. Horizontal bars indicate 
group means. Blood IL-10 producing regulatory B cell and CD24hiCD27+ B cell frequencies 
were determined by FACS.*P<0.01, **P<0.0001.  
 
Figure 2.  Serial change of IL-10 producing regulatory B cell. The modified Rodnan TSS, 
IL-10 producing regulatory B cell and CD24hiCD27+ B cell levels were analysed in 6 indivisual 
patient with dcSSc before and after immunosuppressive treatment.*P<0.05, **P<0.01. 
 
 




